NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Erstveröffentlichung
2013
Metadata only
Search for full text

Wissenschaftlicher Artikel

Authors
Schnaiter, Andrea
Paschka, Peter
Rossi, Marianna
Zenz, Thorsten
Buehler, Andreas
et al.
Faculties
Medizinische Fakultät
Institutions
UKU. Klinik für Innere Medizin III
Published in
Blood ; 122 (2013), 7. - S. 1266-1270. - ISSN 0006-4971
Link to publication
https://dx.doi.org/10.1182/blood-2013-03-488197
Funding information
Else Kroner Fresenius Stiftung (Else Kroner Forschungskolleg Ulm)
CLL Global Research Foundation (Alliance)
Virtual Helmholtz Institute [VH-VI-404, TP2]
DFG [SFB 1074]
Keywords
chronic lymphocytic-leukemia; genomic aberrations; follow-up; survival; progression; prognosis; disease; risk
Dewey Decimal Group
DDC 610 / Medicine & health
Metadata
Show full item record